There are 594 resources available
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast
K-Ras mutations: Novel mechanisms for drugging the undruggable
Presenter: Chiara Ambrogio
Session: Innovation in actionable genomic alterations (AGA)
Resources:
Slides
Webcast
Disparities in lung cancer screening
Presenter: Phil Crosbie
Session: Lung cancer screening
Resources:
Slides
Webcast
2O - SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi
Presenter: Myung-Ju Ahn
Session: Proffered Paper session 1
Resources:
Abstract
Q&A and discussion
Session: Lung cancer screening
Resources:
Webcast
3O - Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
Presenter: Nicolas Girard
Session: Proffered Paper session 1
Resources:
Abstract
1O - Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
Presenter: Xiuning Le
Session: Proffered Paper session 1
Resources:
Abstract
Invited Discussant 2O, 3O and 1O
Presenter: Pei Li Stephanie Saw
Session: Proffered Paper session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast
Liquid biopsy: Principles and pitfalls for the clinician
Presenter: Catherine Alix-Panabieres
Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Resources:
Slides
Webcast